1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-9 of 9 (Search time: 0.004 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
2015Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literatureChan, D.; Pavlakis, N.; Shapiro, J.; Price, T.; Karapetis, C.; Tebbutt, N.; Segelov, E.; Rosell, R.
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerPrice, T.; Bruhn, M.; Lee, C.; Hardingham, J.; Townsend, A.; Mann, K.; Simes, J.; Weickhardt, A.; Wrin, J.; Wilson, K.; Gebski, V.; Van Hazel, G.; Robinson, B.; Cunningham, D.; Tebbutt, N.
2012Biologic therapies in the metastatic colorectal cancer treatment continuum - applying current evidence to clinical practicePeeters, M.; Price, T.
2010Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerPeeters, M.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.; Rong, A.; Gansert, J.
2011Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX Trial of capecitabine alone or in combination with Bevacizumab and Mitomycin in advanced colorectal cancerPrice, T.; Hardingham, J.; Lee, C.; Weickhardt, A.; Townsend, A.; Wrin, J.; Chua, A.; Shivasami, A.; Cummins, M.; Murone, C.; Tebbutt, N.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
2012Cetuximab in metastatic colorectal cancerBroadbridge, V.; Karapetis, C.; Price, T.
2015Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI zlone as second-line treatment for metastatic colorectal cancerPeeters, M.; Oliner, K.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; André, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; He, P.; Yu, H.; Koukakis, R.; Terwey, J.; et al.

Discover